Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,500 Shares of Stock

Key Points

• Insider Selling: Xeris Biopharma Director Marla Persky sold 15,500 shares at $7.72 each, reducing her ownership by 9.84% to 142,000 shares worth approximately $1.1 million.
• Stock Performance: Following the sale, Xeris Biopharma's stock price declined to $7.49, with a market cap of $1.21 billion and a twelve-month high of $8.03.
• Analyst Ratings: Analysts have mixed views on Xeris Biopharma, with five recommending a "Buy" and one a "Hold", while price targets vary from $7.00 to $10.00.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director Marla Persky sold 15,500 shares of the firm's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the transaction, the director directly owned 142,000 shares in the company, valued at approximately $1,096,240. The trade was a 9.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Xeris Biopharma Price Performance

Shares of XERS stock traded up $0.20 during trading hours on Wednesday, reaching $7.67. The company had a trading volume of 1,645,821 shares, compared to its average volume of 1,727,501. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -36.52 and a beta of 0.13. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.69 and a 12 month high of $8.03. The business has a fifty day simple moving average of $6.64 and a 200-day simple moving average of $5.35.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. On average, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analyst Weigh In

XERS has been the subject of several analyst reports. Leerink Partners increased their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a research note on Tuesday, August 19th. Wall Street Zen cut Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Finally, HC Wainwright assumed coverage on Xeris Biopharma in a research report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Xeris Biopharma has an average rating of "Moderate Buy" and an average target price of $7.08.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds have recently made changes to their positions in XERS. Raymond James Financial Inc. bought a new position in Xeris Biopharma in the 4th quarter worth about $45,000. Northern Trust Corp increased its holdings in Xeris Biopharma by 3.3% during the 4th quarter. Northern Trust Corp now owns 1,196,381 shares of the company's stock worth $4,056,000 after acquiring an additional 38,155 shares during the period. BNP Paribas Financial Markets purchased a new stake in Xeris Biopharma in the 4th quarter worth approximately $339,000. Balyasny Asset Management L.P. bought a new position in Xeris Biopharma in the 4th quarter valued at $58,000. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Xeris Biopharma by 38.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,363,452 shares of the company's stock valued at $4,622,000 after purchasing an additional 378,437 shares in the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.